

The Genetic Basis of Peyronie Disease: A Review

Sexual Medicine Reviews

4, 85-94

DOI: [10.1016/j.sxmr.2015.10.002](https://doi.org/10.1016/j.sxmr.2015.10.002)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Peyronieâ€™s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. <i>Translational Andrology and Urology</i> , 2016, 5, 280-289.	0.6	74
2	A propÃ³sito da doenÃ§a de Peyronie. <i>Acta UrolÃ³gica Portuguesa</i> , 2016, 33, 113-114.	0.1	1
3	Contemporary Review of Grafting Techniques for the Surgical Treatment of Peyronie's Disease. <i>Sexual Medicine Reviews</i> , 2017, 5, 544-552.	1.5	63
4	Changes in the Effects of Peyronie's Disease After Treatment With Collagenase <i>Clostridium histolyticum</i> : Male Patients and Their Female Partners. <i>Sexual Medicine</i> , 2017, 5, e124-e130.	0.9	29
5	Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. <i>BJU International</i> , 2017, 120, 717-723.	1.3	83
6	Collagenase Clostridium histolyticum in the Treatment of Peyronie's Diseaseâ€”A Review of the Literature and a New Modified Protocol. <i>Sexual Medicine Reviews</i> , 2017, 5, 529-535.	1.5	28
7	Effect of Penile Traction and Vacuum Erectile Device for Peyronieâ€™s Disease in an Animal Model. <i>Journal of Sexual Medicine</i> , 2017, 14, 1270-1276.	0.3	27
8	Recent Pathophysiological Aspects of Peyronieâ€™s Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatmentâ€”Literature Review. <i>Advances in Urology</i> , 2017, 2017, 1-17.	0.6	30
9	Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase <i>Clostridium Histolyticum</i> Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study. <i>Journal of Sexual Medicine</i> , 2018, 15, 716-721.	0.3	19
11	Aspects of Nanomaterials in Wound Healing. <i>Current Drug Delivery</i> , 2018, 16, 26-41.	0.8	42
12	Contemporary surgical and non-surgical management of Peyronieâ€™s disease. <i>Translational Andrology and Urology</i> , 2018, 7, 603-617.	0.6	14
13	Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the Literature. <i>European Urology</i> , 2018, 74, 767-781.	0.9	45
14	Sildenafil 25 mg ODT+ Collagenase <i>Clostridium hystoliticum</i> vs Collagenase <i>Clostridium hystoliticum</i> Alone for the Management of Peyronieâ€™s Disease: A Matched-Pair Comparison Analysis. <i>Journal of Sexual Medicine</i> , 2018, 15, 1472-1477.	0.3	34
15	Vision and Strategies for Men's Health Research in an Aging Society. <i>World Journal of Men's Health</i> , 2018, 36, 173.	1.7	5
16	Characterization of Septal and Punctate Scarring in Peyronie's Disease. <i>Urology</i> , 2018, 118, 87-91.	0.5	4
17	Reduction in Peyronie's-like plaque size using a vacuum erection device in a rat model of Peyronie's disease via the TGF-Î²/SMAD signalling pathway. <i>Andrologia</i> , 2018, 50, e13051.	1.0	19
18	The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronieâ€™s Disease (PD). <i>International Journal of Impotence Research</i> , 2018, 30, 171-178.	1.0	30
19	Increased Risk of Cancer in Men With Peyronieâ€™s Disease: A Cohort Study Using a Large United States Insurance Claims Database. <i>Sexual Medicine</i> , 2019, 7, 403-408.	0.9	4

#	ARTICLE	IF	CITATIONS
20	Comparative Effectiveness of Intralesional Therapy for Peyronie's Disease in Controlled Clinical Studies: A Systematic Review and Network Meta-Analysis. <i>Journal of Sexual Medicine</i> , 2019, 16, 289-299.	0.3	35
21	Current Strategies in the Management of Peyronie's Disease (PD) – Results of a Survey of 401 Sexual Medicine Experts Across Europe. <i>Journal of Sexual Medicine</i> , 2019, 16, 901-908.	0.3	15
22	The use of penile traction therapy in the management of Peyronie's disease: current evidence and future prospects. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721983813.	0.9	11
23	Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease. <i>Sexual Medicine Reviews</i> , 2019, 7, 679-689.	1.5	33
24	Review of Management Options for Active-Phase Peyronie's Disease. <i>Sexual Medicine Reviews</i> , 2019, 7, 329-337.	1.5	29
25	Urologic conditions associated with malignancy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 23-30.	0.8	2
26	Management of Peyronie's disease with collagenase <i>Clostridium histolyticum</i> in the acute phase. <i>World Journal of Urology</i> , 2020, 38, 299-304.	1.2	14
27	The Etiology of Peyronie's Disease: Pathogenesis and Genetic Contributions. <i>Sexual Medicine Reviews</i> , 2020, 8, 314-323.	1.5	33
28	Erectile Dysfunction and Peyronie's Disease: Genetic Diseases?. <i>European Urology Focus</i> , 2020, 6, 572-574.	1.6	11
29	Intraoperative methods for residual curvature correction during penile prosthesis implantation in patients with Peyronie's disease and refractory erectile dysfunction. <i>International Journal of Impotence Research</i> , 2020, 32, 43-51.	1.0	6
30	New insights into the pathogenesis of Peyronie's disease: A narrative review. <i>Chronic Diseases and Translational Medicine</i> , 2020, 6, 165-181.	0.9	9
31	Intralesional Injection Therapy and Atypical Peyronie's Disease: A Systematic Review. <i>Sexual Medicine Reviews</i> , 2021, 9, 434-444.	1.5	6
34	Future concepts and therapy approaches for Peyronie's disease. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 273-284.	0.5	0
35	Peyronie's disease: new paradigm for the treatment of a unique cause of erectile dysfunction. <i>Postgraduate Medicine</i> , 2020, 132, 4-8.	0.9	4
36	Nonsurgical treatment option for Peyronie's disease: shockwave therapy. , 2020, , 47-63.		0
37	Unwinding Fibrosis in Peyronie's Disease. <i>Journal of Sexual Medicine</i> , 2020, 17, 838-840.	0.3	5
38	About the drawback of collagenase. <i>International Journal of Impotence Research</i> , 2020, 33, 570-571.	1.0	1
39	Prevalence of Peyronie and Ledderhose Diseases in a Series of 730 Patients with Dupuytren Disease. <i>Plastic and Reconstructive Surgery</i> , 2020, 145, 978-984.	0.7	9

#	ARTICLE	IF	CITATIONS
40	A clinical pathway for the management of Peyronieâ€™s disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association. <i>BJU International</i> , 2020, 126, 12-17.	1.3	23
41	Unwinding Fibrosis in Peyronie's Disease. <i>Journal of Sexual Medicine</i> , 2020, 17, 835-837.	0.3	1
42	Peyronieâ€™s disease: is it genetic or not?. <i>Translational Andrology and Urology</i> , 2020, 9, S262-S268.	0.6	11
43	Minimally invasive therapies for Peyronieâ€™s disease: the current state of the art. <i>Translational Andrology and Urology</i> , 2020, 9, S269-S283.	0.6	7
44	Fibroproliferative disorders and diabetes: Understanding the pathophysiologic relationship between Peyronieâ€™s disease, Dupuytren disease and diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00195.	1.0	10
45	Implications of Calcification in Peyronie's Disease, A Review of the Literature. <i>Urology</i> , 2021, 152, 52-59.	0.5	5
46	Focusing on sexual rehabilitation besides penile rehabilitation following radical prostatectomy is important. <i>International Journal of Impotence Research</i> , 2021, 33, 448-456.	1.0	3
47	Patients with Dupuytrenâ€™s Contracture, Ledderhose Disease, and Peyronieâ€™s Disease are at higher risk of arthrofibrosis following total knee arthroplasty. <i>Knee</i> , 2021, 29, 190-200.	0.8	6
48	Molecular Mechanisms and Current Pharmacotherapy of Peyronieâ€™s Disease: A Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 643641.	1.6	13
49	Safety and Efficacy Study of Collagenase Clostridium Histolyticum Applied With an Intensive Protocol in the Treatment of Peyronie's Disease. <i>Sexual Medicine</i> , 2021, 9, 100375-100375.	0.9	4
50	Urologistsâ€™ knowledge base and practice patterns in Peyronieâ€™s disease. A national survey of members of the Italian andrology society. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 348-355.	0.4	0
51	The Natural History of Peyronie's Disease. <i>World Journal of Men's Health</i> , 2021, 39, 399.	1.7	27
52	Long-term patient-reported outcomes in men with Peyronieâ€™s disease undergoing nonsurgical and nonintralesional injection management. <i>International Journal of Impotence Research</i> , 2021, 33, 75-81.	1.0	6
53	Modern Non-Surgical Treatment Strategies for Peyronieâ€™s Disease. , 2020, , 467-481.		0
54	Epidemiology and etiology. , 2020, , 3-12.		0
55	Conventional intralesional injection therapies. , 2020, , 91-103.		0
56	ABO Blood Type and Risk of Peyronieâ€™s Disease in Japanese Males. <i>World Journal of Men's Health</i> , 2022, 40, 509.	1.7	5
57	Shock Wave Therapy for Peyronie's Diseaseâ€”Learning From the Past and Looking Into the Future. <i>Journal of Sexual Medicine</i> , 2022, , .	0.3	0

#	ARTICLE	IF	CITATIONS
58	Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: An Evidence-Based Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 780956.	1.2	2
59	Whole-Genome Sequencing Identifies Novel Heterozygous Mutation in ALMS1 in Three Men With Both Peyronie's and Dupuytren's Disease. <i>Urology</i> , 2022, 166, 76-78.	0.5	3
60	Peyronie's disease - today's treatment options. <i>Urologie Pro Praxi</i> , 2021, 22, 143-147.	0.0	0
61	Induratio penis plastica. <i>Urologie Pro Praxi</i> , 2020, 21, 113-118.	0.0	0
62	Global Perspective on the Management of Peyronie's Disease. <i>Frontiers in Reproductive Health</i> , 0, 4, .	0.6	2
63	Peyronie's disease development and management in diabetic men. <i>Andrology</i> , 0, , .	1.9	2
64	Significant familial clustering of Peyronie's disease in close and distant relatives. <i>Andrology</i> , 2022, 10, 1361-1367.	1.9	2
65	Significant inverse association of testosterone level with penile deformity severity in Japanese males with Peyronie's disease. <i>International Journal of Urology</i> , 0, , .	0.5	2
66	The efficacy and safety of intralesional injection of collagenase Clostridium histolyticum for Peyronie's disease: A meta-analysis of published prospective studies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
67	Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease. <i>PLoS ONE</i> , 2022, 17, e0277646.	1.1	3
68	Role of Oxidative Stress in Peyronie's Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15969.	1.8	10
69	Congenital penile curvature as a possible risk factor for the onset of Peyronie's disease, and psychological consequences of penile curvature. <i>Archivio Italiano Di Urologia Andrologia</i> , 0, , .	0.4	3
70	Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie's disease. <i>Journal of Sexual Medicine</i> , 2023, 20, 925-934.	0.3	1